Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Heron Therapeutics (HRTX) EBITDA Margin (2016 - 2026)

Heron Therapeutics filings provide 13 years of EBITDA Margin readings, the most recent being 23.4% for Q1 2026.

  • On a quarterly basis, EBITDA Margin fell 3014.0% to 23.4% in Q1 2026 year-over-year; TTM through Mar 2026 was 20.53%, a 1530.0% decrease, with the full-year FY2025 number at 13.04%, down 363.0% from a year prior.
  • EBITDA Margin hit 23.4% in Q1 2026 for Heron Therapeutics, down from 7.27% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 8.92% in Q4 2024 to a low of 272.37% in Q1 2022.
  • Median EBITDA Margin over the past 5 years was 31.29% (2023), compared with a mean of 68.87%.
  • Biggest five-year swings in EBITDA Margin: soared 19853bps in 2022 and later tumbled -3115bps in 2025.
  • Heron Therapeutics' EBITDA Margin stood at 66.04% in 2022, then skyrocketed by 53bps to 31.29% in 2023, then surged by 128bps to 8.92% in 2024, then crashed by -182bps to 7.27% in 2025, then tumbled by -222bps to 23.4% in 2026.
  • The last three reported values for EBITDA Margin were 23.4% (Q1 2026), 7.27% (Q4 2025), and 45.78% (Q3 2025) per Business Quant data.